Eculizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
Eculizumab biosimilar L234A L235A P329G (LALAPG) Fc silent mutant (anti-human C5 monoclonal antibody) is used for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by eculizumab.
Synonyms: the terminal Complement component 5
产品参数
| 货号 | C022P-AAG |
|---|---|
| 产品名称 | Eculizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 同种型 | Human IgG2/4 kappa. |
| 来源 | The anti-human C5 monoclonal antibody Eculizumab biosimilar L234A L235A P329G (LALAPG) Fc silent mutant was produced in mammalian cells. |
| 特异性 | The in vivo grade Eculizumab biosimilar 234A L235A P329G (LALAPG) Fc silent mutant specifically binds to the human C5, the terminal complement component 5. |
| 抗体形式 | 0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives. |
| 内毒素 | < 0.1 EU per 1 ug of the protein by the LAL method. |
| 纯度 | >95% by SDS-PAGE under reducing conditions and HPLC. |
| 运输 | The recombinant monoclonal antibody Eculizumab L234A L235A P329G (LALAPG) Fc silent mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| 稳定性与存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| 注意事项 | Eculizumab biosimilar CHO stable cell line is available for licensing to manufacture the eculizumab biosimilar protein. The research grade eculizumab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls and recombinant human IgG2 isotype controls are available. |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
文献
C022P-AAG: Eculizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
Recombinant Humanized IgG2 Monoclonal Antibody.
Background
Eculizumab, a recombinant humanized anti-C5 (the terminal Complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) with excessive destruction of red blood cells (hemolysis). Eculizumab is also the first agent to treat atypical hemolytic uremic syndrome (aHUS) with abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.